Abstract: The invention provides BASB010 polypeptides and polynucleotides encoding BASB010 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
Abstract: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent inducers of a range of immune responses.
Type:
Grant
Filed:
February 24, 2000
Date of Patent:
September 23, 2003
Assignee:
SmithKline Beecham Biologicals s.a.
Inventors:
Patricia Marie Momin, Nathalie Marie-Josephe Garcon
Abstract: Provided are BASB011 polypeptides and polynucleotides encoding BASB011 polypeptide from Moraxella catarrhalis. Also provided are immunogenic uses.
Abstract: Provided are Moraxella catarrhalis BASB034 polypeptides and immnunogenic fragments of BASB034 polypeptides Preferably, the immunogenic fragments have at least 15 amino acids that match an aligned contiguous segment of SEQ ID NOs:2, 4, 6 or 8. The immunogenic fragments, when administered to a subject in a suitable composition (which can include an adjuvant, or a suitable carrier coupled to the fragment) raise an immune response that recognizes a polypeptide having the sequence of SEQ ID NOs:2, 4, 6 or 8. The invention further provides immunogenic compositions containing BASB034 polypeptides and immunogenic fragments thereof, and a pharmaceutically acceptable carrier. Also provided are fusion proteins that contain BASB034 polypeptides and immunogenic fragments thereof.
Abstract: The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, preferably the saponins used in said adjuvant combinations are haemolytic. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments.
Abstract: The invention provides serum-free media for the culture of drosophila insect cells. The serum-free media of the invention comprise a basal medium to which is added yeast hydrolysate, and albumin or dextran. In another embodiment of the invention, albumin hydrolysate is added to the basal medium, in addition to the aforementioned compounds.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
June 24, 1997
Assignee:
SmithKline Beecham Corporation
Inventors:
Luciano Ramos, Amy Anne Murnane, Melvin Susumu Oka
Abstract: The present invention provides mammalian cells modified to stably express at least the entire human immunodeficiency virus-1 envelope protein gp160. The invention provides a vaccine comprising the cells of the invention. The invention also provides methods for screening compounds for their ability to inhibit formation of syncytia between cells that express HIV-1 gp160 and cells that express CD4 comprising mixing cells of invention, cells that express CD4 on their surfaces, and a test compound for a length of time sufficient for syncytia to form; and then determining the amount of syncytia formation.
Type:
Grant
Filed:
June 2, 1995
Date of Patent:
December 3, 1996
Assignee:
SmithKline Beecham Corporation
Inventors:
Zdenka L. Jonak, Christine Debouck, Robert Clark, Stephen Trulli
Abstract: The present invention provides mammalian cells modified to stably express at least the entire human immunodeficiency virus-1 envelope protein gp160. The invention provides a vaccine comprising the cells of the invention. The invention also provides methods for screening compounds for their ability to inhibit formation of syncytia between cells that express HIV-1 gp160 and cells that express CD4 comprising mixing cells of invention, cells that express CD4 on their surfaces, and a test compound for a length of time sufficient for syncytia to form; and then determining the amount of syncytia formation.
Type:
Grant
Filed:
October 8, 1993
Date of Patent:
October 31, 1995
Assignee:
SmithKline Beecham Corporation
Inventors:
Zdenka L. Jonak, Christine Debouck, Robert Clark, Stephen Trulli
Abstract: A process is provided for the purification of pertussis toxin (PT) and/or filamentous hemagglutinin antigen (FHA) from a B. pertussis fermentation broth or cell free culture supernatant containing at least one antigen, which comprises contacting the fermenation broth or cell free culture supernatant with a hydroxyapatite adsorbent for a sufficient time to adsorb the antigen(s) at a pH which both PT and FHA are adsorbed and eluting a mixture containing the adsorbed antigen(s) from the adsorbent with eluant at a pH which both PT and FHA are eluted. The PT and FHA may be further purified by two sequential chromatographic columns, one of which involves apolar-ligand chromatography.
Abstract: A method for purifying tPA or a plasminogen activator having an active site resembling that of tPA from an impure solution thereof which comprises contacting the impure solution with a solid support having bound thereto a tripeptide of the formula: -X-Y-argininal, wherein X and Y are amino acids selected from the group consisting of pro, phe, trp and tyr. The method is also used with a tripeptide of the formula: -phe-Y-argininal, wherein Y is selected from the group consisting of phe, pro, trp, tyr, val, ile and glu(PEA).